Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TR), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the TR for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.

Viking Therapeutics, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

ORAL VK2735 DEMONSTRATED EARLY, PROGRESSIVE WEIGHT LOSS FROM WEEK 1 THROUGH WEEK 13 WITHOUT A PLATEAU DOSE-DEPENDENT WEIGHT LOSS OBSERVED ACROSS ALL VK2735 COHORTS, WITH THE HIGHEST DOSE ACHIEVING A MEAN REDUCTION OF UP TO 12.2% (26.6 LBS) FROM BASELINE AT WEEK 13 BASELINE CHARACTERISTICS IN THE ONGOING PHASE 3 VANQUISH-1 STUDY OF VK2735 IN ADULTS WITH OBESITY WERE ALSO PRESENTED IN A SECOND POSTER AT THE CONFERENCE SAN DIEGO, MAY 12, 2026 /PRNEWSWIRE/ -- VIKING THERAPEUTICS, INC. ("VIKING") (NASDAQ: VKTX), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DEVELOPMENT OF NOVEL THERAPIES FOR METABOLIC AND ENDOCRINE DISORDERS, TODAY PRESENTED ADDITIONAL DATA FROM ITS PHASE 2 VENTURE-ORAL DOSING TRIAL EVALUATING THE ORAL TABLET FORMULATION OF VK2735 AT THE EUROPEAN CONGRESS ON OBESITY (ECO) IN ISTANBUL, TRKIYE. VK2735 IS A DUAL AGONIST OF THE GLUCAGON-LIKE PEPTIDE 1 (GLP-1) AND GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE (GIP) RECEPTORS, IN DEVELOPMENT WITH SUBCUTANEOUS AND ORAL FORMULATIONS FOR THE POTENTIAL TREATMENT OF VARIOUS METABOLIC DISORDERS.

VIKING THERAPEUTICS PRESENTS DATA FROM ITS 13-WEEK PHASE 2 VENTURE-ORAL DOSING TRIAL OF VK2735 AT EUROPEAN CONGRESS ON OBESITY (ECO) 2026

POSTER PRESENTATIONS HIGHLIGHT DATA FROM 13-WEEK PHASE 2 VENTURE-ORAL TRIAL OF VK2735 AND PARTICIPANT CHARACTERISTICS FROM PHASE 3 VANQUISH-1 TRIAL OF SUBCUTANEOUS VK2735 SAN DIEGO, MAY 5, 2026 /PRNEWSWIRE/ --VIKING THERAPEUTICS, INC. ("VIKING") (NASDAQ: VKTX), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DEVELOPMENT OF NOVEL THERAPIES FOR METABOLIC AND ENDOCRINE DISORDERS, ANNOUNCED TODAY THAT IT WILL PRESENT TWO POSTERS ON ITS VK2735 PROGRAM AT THE 33RD EUROPEAN CONGRESS ON OBESITY (ECO) TAKING PLACE IN ISTANBUL, TRKIYE ON MAY 12-15, 2026. VK2735 IS A DUAL AGONIST OF THE GLUCAGON-LIKE PEPTIDE 1 (GLP-1) AND GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE (GIP) RECEPTORS THAT VIKING IS DEVELOPING IN SUBCUTANEOUS AND ORAL FORMULATIONS FOR THE POTENTIAL TREATMENT OF VARIOUS METABOLIC DISORDERS, INCLUDING OBESITY.

VIKING THERAPEUTICS ANNOUNCES TWO POSTER PRESENTATIONS AT EUROPEAN CONGRESS ON OBESITY (ECO) 2026

CONFERENCE CALL SCHEDULED FOR 4:30 P.M. ET TODAY -- PHASE 3 VANQUISH TRIALS FOR SUBCUTANEOUS VK2735 IN OBESITY ADVANCE; VANQUISH-1 AND VANQUISH-2 TRIALS FULLY ENROLLED -- -- INITIATION OF PHASE 3 ORAL VK2735 TRIAL FOR OBESITY EXPECTED 4Q26 -- -- VK2735 MAINTENANCE DOSING STUDY ONGOING; DATA EXPECTED 3Q26 -- -- IND FILED FOR NOVEL AMYLIN AGONIST VK3019; PHASE 1 TRIAL INITIATION EXPECTED 2Q26 -- -- STRONG QUARTER-END CASH POSITION OF$603 MILLION -- SAN DIEGO, APRIL 29, 2026 /PRNEWSWIRE/ --VIKING THERAPEUTICS, INC. (VIKING) (NASDAQ: VKTX), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DEVELOPMENT OF NOVEL THERAPIES FOR METABOLIC AND ENDOCRINE DISORDERS, TODAY ANNOUNCED ITS FINANCIAL RESULTS FOR THE FIRST QUARTER ENDEDMARCH 31, 2026, AND PROVIDED AN UPDATE ON ITS CLINICAL PIPELINE AND OTHER CORPORATE DEVELOPMENTS.

VIKING THERAPEUTICS REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

CONFERENCE CALL SCHEDULED FOR  WEDNESDAY, APRIL 29 AT 4:30 P.M. EASTERN TIME  SAN DIEGO, APRIL 22, 2026 /PRNEWSWIRE/ -- VIKING THERAPEUTICS, INC. ("VIKING") (NASDAQ: VKTX), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DEVELOPMENT OF NOVEL THERAPIES FOR METABOLIC AND ENDOCRINE DISORDERS, TODAY ANNOUNCED THAT THE COMPANY WILL RELEASE FINANCIAL RESULTS FOR THE FIRST QUARTER OF 2026 AFTER THE MARKET CLOSE ONWEDNESDAY, APRIL 29, 2026.

VIKING THERAPEUTICS TO REPORT FINANCIAL RESULTS FOR FIRST QUARTER 2026 ON APRIL 29, 2026

SAN DIEGO, APRIL 10, 2026 /PRNEWSWIRE/ -- VIKING THERAPEUTICS, INC. ("VIKING") (NASDAQ: VKTX), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DEVELOPMENT OF NOVEL THERAPIES FOR METABOLIC AND ENDOCRINE DISORDERS, TODAY ANNOUNCED THAT THE COMPANY WILL ATTEND MULTIPLE UPCOMING INVESTOR CONFERENCES. DETAILS OF THE COMPANY'S PARTICIPATION ARE AS FOLLOWS: RAYMOND JAMES BIOTECH/BIOPHARMA CONFERENCE 2026 DETAILS: VIKING MANAGEMENT WILL PARTICIPATE IN 1-ON-1 MEETINGSCONFERENCE DATE: APRIL 14, 2026LOCATION: NEW YORK, NY PIPER SANDLER SPRING BIOPHARMA SYMPOSIUM 2026 DETAILS: VIKING MANAGEMENT WILL PARTICIPATE IN 1-ON-1 MEETINGS CONFERENCE DATE: APRIL 16, 2026LOCATION: BOSTON, MA ABOUT VIKING THERAPEUTICS, INC. VIKING THERAPEUTICS, INC. IS A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DEVELOPMENT OF NOVEL FIRST-IN-CLASS OR BEST-IN-CLASS THERAPIES FOR THE TREATMENT OF METABOLIC AND ENDOCRINE DISORDERS.

VIKING THERAPEUTICS TO PARTICIPATE AT UPCOMING INVESTOR CONFERENCES

78-WEEK STUDY EVALUATING SUBCUTANEOUS VK2735 IN ADULTS WITH OBESITY AND TYPE 2 DIABETES SAN DIEGO, MARCH 26, 2026 /PRNEWSWIRE/ --VIKING THERAPEUTICS, INC. (VIKING) (NASDAQ: VKTX), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DEVELOPMENT OF NOVEL THERAPIES FOR METABOLIC AND ENDOCRINE DISORDERS, TODAY ANNOUNCED THE COMPLETION OF PATIENT ENROLLMENT IN ITS PHASE 3 VANQUISH-2 CLINICAL TRIAL OF SUBCUTANEOUS VK2735, THE COMPANY'S DUAL AGONIST OF THE GLUCAGON-LIKE PEPTIDE 1 (GLP-1) AND GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE (GIP) RECEPTORS. VK2735 IS BEING DEVELOPED IN BOTH ORAL AND SUBCUTANEOUS FORMULATIONS FOR THE POTENTIAL TREATMENT OF METABOLIC DISORDERS SUCH AS OBESITY.

VIKING THERAPEUTICS ANNOUNCES COMPLETION OF ENROLLMENT IN PHASE 3 VANQUISH-2 TRIAL OF VK2735

SAN DIEGO, MARCH 5, 2026 /PRNEWSWIRE/ -- VIKING THERAPEUTICS, INC. ("VIKING") (NASDAQ: VKTX), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DEVELOPMENT OF NOVEL THERAPIES FOR METABOLIC AND ENDOCRINE DISORDERS, TODAYANNOUNCED THAT THE COMPANY WILL PARTICIPATE AT MULTIPLE UPCOMING INVESTOR CONFERENCES. DETAILS OF THE COMPANY'S PARTICIPATION ARE AS FOLLOWS: LEERINK PARTNERS GLOBAL HEALTHCARE CONFERENCE 2026 DETAILS: VIKING MANAGEMENT WILL PARTICIPATE IN A FIRESIDE CHAT AND IN 1-ON-1 MEETINGSCONFERENCE DATE: MARCH 8-11, 2026FIRESIDE CHAT TIMING: 10:40  11:10 A.M.

CONFERENCE CALL SCHEDULED FOR 4:30 P.M. ET TODAY ORAL VK2735 TO ADVANCE INTO PHASE 3 FOR OBESITY IN 3Q26 PHASE 3 VANQUISH TRIALS FOR SUBCUTANEOUS VK2735 IN OBESITY ONGOING; VANQUISH-1 ENROLLMENT COMPLETE, VANQUISH-2 NEARING FULL ENROLLMENT VK2735 MAINTENANCE DOSING STUDY FULLY ENROLLED; DATA EXPECTED 3Q26 NOVEL AMYLIN AGONIST IND FILING PLANNED THIS QUARTER STRONG QUARTER-END CASH POSITION OF $706 MILLION SAN DIEGO, FEB. 11, 2026 /PRNEWSWIRE/ -- VIKING THERAPEUTICS, INC. (VIKING) (NASDAQ: VKTX), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DEVELOPMENT OF NOVEL THERAPIES FOR METABOLIC AND ENDOCRINE DISORDERS, TODAY ANNOUNCED ITS FINANCIAL RESULTS FOR THE FOURTH QUARTER AND YEAR ENDED DECEMBER 31, 2025, AND PROVIDED AN UPDATE ON ITS CLINICAL PIPELINE AND OTHER CORPORATE DEVELOPMENTS.

VIKING THERAPEUTICS REPORTS FOURTH QUARTER AND YEAR-END 2025 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

CONFERENCE CALL SCHEDULED FOR WEDNESDAY, FEBRUARY 11 AT 4:30 P.M. EASTERN TIME SAN DIEGO, FEB. 4, 2026 /PRNEWSWIRE/ --VIKING THERAPEUTICS, INC. ("VIKING") (NASDAQ: VKTX), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DEVELOPMENT OF NOVEL THERAPIES FOR METABOLIC AND ENDOCRINE DISORDERS, TODAY ANNOUNCED THAT THE COMPANY WILL RELEASE FINANCIAL RESULTS FOR THE FOURTH QUARTER AND YEAR-END 2025 AFTER THE MARKET CLOSE ON WEDNESDAY, FEBRUARY 11, 2026.

VIKING THERAPEUTICS TO REPORT FINANCIAL RESULTS FOR FOURTH QUARTER AND YEAR-END 2025 ON FEBRUARY 11, 2026

PUBLICATION HIGHLIGHTS IMPRESSIVE WEIGHT LOSS OF UP TO 14.7% FROM BASELINE AFTER 13 WEEKS OF TREATMENT; NO PLATEAU OBSERVED VK2735 CURRENTLY BEING EVALUATED IN VANQUISH PHASE 3 REGISTRATIONAL PROGRAM IN OBESITY SAN DIEGO, JAN. 12, 2026 /PRNEWSWIRE/ -- VIKING THERAPEUTICS, INC. (VIKING) (NASDAQ: VKTX), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DEVELOPMENT OF NOVEL THERAPIES FOR METABOLIC AND ENDOCRINE DISORDERS, TODAY ANNOUNCED THE PUBLICATION OF THE RESULTS OF THE COMPANY'S PHASE 2 VENTURE CLINICAL TRIAL OF VK2735, A DUAL AGONIST OF THE GLUCAGON-LIKE PEPTIDE 1 (GLP-1) AND GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE (GIP) RECEPTORS. VK2375 IS BEING DEVELOPED IN BOTH ORAL AND SUBCUTANEOUS FORMULATIONS FOR THE POTENTIAL TREATMENT OF VARIOUS METABOLIC DISORDERS SUCH AS OBESITY.

VIKING THERAPEUTICS ANNOUNCES PUBLICATION OF RESULTS FROM PHASE 2 VENTURE TRIAL OF DUAL GLP-1/GIP RECEPTOR AGONIST VK2735 IN THE JOURNAL OBESITY

STUDY IS EVALUATING MONTHLY SUBCUTANEOUS, WEEKLY ORAL, AND DAILY ORAL REGIMENS DESIGNED TO EXPLORE MAINTENANCE DOSING REGIMENS FOLLOWING INITIAL WEIGHT LOSS WITH VK2735 SAN DIEGO, JAN. 8, 2026 /PRNEWSWIRE/ -- VIKING THERAPEUTICS, INC. (VIKING) (NASDAQ: VKTX), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DEVELOPMENT OF NOVEL THERAPIES FOR METABOLIC AND ENDOCRINE DISORDERS, TODAY ANNOUNCED THE COMPLETION OF PATIENT ENROLLMENT IN ITS EXPLORATORY MAINTENANCE DOSING STUDY OF VK2735, THE COMPANY'S DUAL AGONIST OF THE GLUCAGON-LIKE PEPTIDE 1 (GLP-1) AND GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE (GIP) RECEPTORS. VK2375 IS BEING DEVELOPED IN BOTH ORAL AND SUBCUTANEOUS FORMULATIONS FOR THE POTENTIAL TREATMENT OF VARIOUS METABOLIC DISORDERS SUCH AS OBESITY.

Viking Therapeutics, Inc.

VKTX

Price

Financial Reports

No items found.

Press Releases

Viking Therapeutics, Inc.

VKTX.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

VKTX